
Oncology NEWS International
- Oncology NEWS International Vol 15 No 4
- Volume 15
- Issue 4
FDA Grants Dasatinib Priority Review for Resistant CML
The FDA has granted priority review to dasatinib (BMS-354825), developed by Bristol-Myers Squibb, for treatment of imatinib (Gleevec)-resistant or refractory chronic myelogenous leukemia (CML) in adults.
PRINCETON, New JerseyThe FDA has granted priority review to dasatinib (BMS-354825), developed by Bristol-Myers Squibb, for treatment of imatinib (Gleevec)-resistant or refractory chronic myelogenous leukemia (CML) in adults. Dasatinib, an oral, small-molecule tyrosine kinase inhibitor, exhibits greater potency than imatinib and inhibits the majority of kinase mutations resistant to imatinib. The new drug application also seeks approval of dasatinib for treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
Articles in this issue
almost 20 years ago
Phase II Trial of Velcade/Alimta Initiated in Advanced NSCLCalmost 20 years ago
ONS Annual Congress Heralds Start of Oncology Nursing Monthalmost 20 years ago
All-Star Panel Spells Out Onc Promises, Problemsalmost 20 years ago
Surveillance for Colon, Breast Ca Falls Off 5 Years After Diagnosisalmost 20 years ago
ODAC Says No to Gemzar for Ovarian Caalmost 20 years ago
Femara Effective Even After Years of No Therapyalmost 20 years ago
XMRV Retrovirus Found in Some Prostate Ca'salmost 20 years ago
Taxotere Wins FDA Approval for Advanced Gastric CancerNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.



































